AARD Aardvark Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1774857 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.2%
TTM EPS YoY22.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-80.9%
ROA-73.5%
ROIC (approx.)-149.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets11.1%
Debt / equity0.00x
Current ratio9.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | — |
| R&D expense | $48.94M | $17.36M |
| SG&A expense | $13.79M | $5.30M |
| Operating income | -$62.73M | -$22.79M |
| Income tax | $0 | $0 |
| Net income | -$57.59M | -$20.59M |
| EBITDA | -$62.69M | -$22.77M |
| EPS (basic) | -2.93 | -5.15 |
| EPS (diluted) | -2.93 | -5.15 |
| Weighted avg. shares (diluted) | 19.62M | 4.00M |
| Balance sheet | ||
| Cash & equivalents | $47.05M | $61.64M |
| Short-term investments | $62.98M | $12.02M |
| Current assets | $111.89M | $74.14M |
| Total assets | $117.18M | $77.51M |
| Current liabilities | $10.55M | $4.93M |
| Total liabilities | $10.55M | $5.39M |
| Shareholders' equity | $106.63M | -$54.64M |
| Shares outstanding | 21.82M | 4.07M |
| Cash flow statement | ||
| Operating cash flow | -$54.17M | -$18.09M |
| Capital expenditure | $95,000 | $109,000 |
| Free cash flow | -$54.27M | -$18.20M |
| Investing cash flow | -$49.67M | -$12.00M |
| Financing cash flow | $89.25M | $81.99M |
| Depreciation & amortization | $36,000 | $16,000 |
| Stock-based compensation | $3.95M | $439,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.